<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="169">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04473352</url>
  </required_header>
  <id_info>
    <org_study_id>COVID Fluids</org_study_id>
    <nct_id>NCT04473352</nct_id>
  </id_info>
  <brief_title>COVID-19 Detection Tests in Different Body Fluids</brief_title>
  <official_title>Diagnostic Accuracy of COVID-19 Detection Tests in Different Body Fluids of Infected Men and Concordance With Viral Cultures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universidade Federal do Cear√°</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical and experimental study will be carried out in which the clinician will investigate
      the PCR of the virus early in different body fluids (blood, semen, urine, saliva) and monitor
      its experimental clearance and evaluate in vitro diagnostic tests and inhibitory factors of
      viral proliferation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The World Health Organization (WHO) declared Coronavirus 2019 (COVID-19) as a pandemic on
      March 11, 2020. Due to the rapid spread of the severe acute respiratory syndrome coronavirus
      2 virus (SARS-CoV-2), we are currently facing an unprecedented global situation. One of the
      main pillars in the control of an epidemic is the performance of large-scale tests providing
      a quick and accurate diagnosis so that the authorities can take timely action. Therefore,
      tests for COVID-19 should be prompt, widely available, and implemented outside the hospital
      environment, to avoid overloading the health system and decreasing the risks of hospital
      transmission to other patients and health professionals. Although universal testing is a
      cornerstone for reducing the burden of COVID-19, the accuracy of the commercially available
      tests for COVID-19 in Brazil remains uncertain. In addition, the natural history of the
      disease in the different organs and tissues is not unquestionably known, nor because the
      virus develops better in some tissues and not others. There are still many unanswered
      questions regarding COVID-19. allow more accurate knowledge of the natural history of the
      disease in the timeline taking into account the acute and long-term phases. Several families
      of viruses can affect the male genitourinary system, as is the case of the Zika (ZKV) and
      Ebola viruses. There are reports that in young patients infected with ZKV, the virus persists
      in semen for up to 6 months after the symptomatic condition. The other SARS-CoV-1 itself was
      detected in human testicles associated with an inflammatory process (orchiepididymitis),
      suggesting the possibility that these viruses could also be detected in the semen. As
      SARS-CoV-1 was able to overcome the hemato-gestural barrier and induce severe testicular
      damage in the previous outbreak, it is possible that men infected with COVID-19 may also have
      testicular damage. Another question that remains unanswered is whether the coronavirus can
      remain in the body of people considered recovered from Covid-19 for an indefinite period. It
      is also unknown whether there are molecules in the body fluids capable of inhibiting viral
      growth. The expected benefits are related to a better understanding of COVID's natural
      history19 and which body fluids can contribute to understanding the pathophysiology of the
      disease. It will be possible to identify the best time and the test with the best accuracy to
      diagnose the disease. It is our intention to identify substances in body fluids with an
      antiviral effect
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Accuracy of Covid19 Detection</measure>
    <time_frame>September 2021</time_frame>
    <description>Numerical variables will be described by measurements of central tendency (mean or median) and the respective dispersion measurements. Categorical variables will be described by their absolute values, percentages, or proportions. To compare the differences of continuous variables, we will use the Student t-test or the Mann-Whitney test. For comparison of categorical data, we will use the chi-square test. Univariable and multivariable analyses will be performed to identify predictors of COVID-19 detection.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Single Group</arm_group_label>
    <description>Patients with suspected acute viral status for COVID 19 will be invited to participate in the identification of the first symptoms. The diagnosis of COVID-19 will be confirmed according to the determinations of the MS through the reaction of qRT-PCR in the nasopharynx swab. Patients will undergo multiple collections of biological material including blood, saliva, semen, and urine. Each patient will be subjected to serial sample collections. The samples will be processed and analyzed for the presence of viral RNA. Patients with 2 consecutive negative samples did not need to perform subsequent collections.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Semen, urine, and saliva: Semen samples will be obtained by the patient through masturbation,
      and collected in sterile containers. Urine samples will be collected from the medium stream
      at least 4 hours without emptying the bladder. Saliva samples will be obtained by the swab.
      The first sample will be collected in the first 14 days after the onset of symptoms and the
      others on a monthly basis. After 2 consecutive negative samples, no more samples will be
      taken. Only the virus will be researched using qRT-PCR. Peripheral blood: Samples of
      peripheral blood are collected through peripheral venipuncture. These samples will be
      collected at the time of inclusion in the study to assess the viral load, and 45 days after
      the onset of symptoms to determine the serum levels of sex hormones.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult male patients with suspected acute viral status for COVID 19 of the city of
        Fortaleza, Ceara, Brazil, who agreed to participate in the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects over the age of 18 years

          -  Agreement with the IC

        Exclusion Criteria:

          -  History of previous prostate surgery or vasectomy

          -  Inability to assess participation in the study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ricardo Reges, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nucleo de Pesquisa e Desenvolvimento de Medicamentos</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ricardo Reges, PhD</last_name>
    <phone>+55 85 996479789</phone>
    <email>ricardoreges@me.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eduardo P Miranda, PhD</last_name>
    <phone>+55 85 991960998</phone>
    <email>mirandaedp@gmail.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Koh D, Cunningham AC. Counting Coronavirus Disease 2019 (COVID-19) Cases: Case Definitions, Screened Populations and Testing Techniques Matter. Ann Acad Med Singap. 2020 Mar;49(3):161-165.</citation>
    <PMID>32301478</PMID>
  </reference>
  <reference>
    <citation>Lin C, Xiang J, Yan M, Li H, Huang S, Shen C. Comparison of throat swabs and sputum specimens for viral nucleic acid detection in 52 cases of novel coronavirus (SARS-Cov-2)-infected pneumonia (COVID-19). Clin Chem Lab Med. 2020 Jun 25;58(7):1089-1094. doi: 10.1515/cclm-2020-0187.</citation>
    <PMID>32301745</PMID>
  </reference>
  <reference>
    <citation>Ling Y, Xu SB, Lin YX, Tian D, Zhu ZQ, Dai FH, Wu F, Song ZG, Huang W, Chen J, Hu BJ, Wang S, Mao EQ, Zhu L, Zhang WH, Lu HZ. Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. Chin Med J (Engl). 2020 May 5;133(9):1039-1043. doi: 10.1097/CM9.0000000000000774.</citation>
    <PMID>32118639</PMID>
  </reference>
  <reference>
    <citation>Lippi G, Simundic AM, Plebani M. Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19). Clin Chem Lab Med. 2020 Jun 25;58(7):1070-1076. doi: 10.1515/cclm-2020-0285.</citation>
    <PMID>32172228</PMID>
  </reference>
  <reference>
    <citation>Liu R, Ma Q, Han H, Su H, Liu F, Wu K, Wang W, Zhu C. The value of urine biochemical parameters in the prediction of the severity of coronavirus disease 2019. Clin Chem Lab Med. 2020 Jun 25;58(7):1121-1124. doi: 10.1515/cclm-2020-0220.</citation>
    <PMID>32286242</PMID>
  </reference>
  <reference>
    <citation>Mardani R, Ahmadi Vasmehjani A, Zali F, Gholami A, Mousavi Nasab SD, Kaghazian H, Kaviani M, Ahmadi N. Laboratory Parameters in Detection of COVID-19 Patients with Positive RT-PCR; a Diagnostic Accuracy Study. Arch Acad Emerg Med. 2020 Apr 4;8(1):e43. eCollection 2020.</citation>
    <PMID>32259132</PMID>
  </reference>
  <reference>
    <citation>Padoan A, Cosma C, Sciacovelli L, Faggian D, Plebani M. Analytical performances of a chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG and antibody kinetics. Clin Chem Lab Med. 2020 Jun 25;58(7):1081-1088. doi: 10.1515/cclm-2020-0443.</citation>
    <PMID>32301749</PMID>
  </reference>
  <reference>
    <citation>Pan F, Xiao X, Guo J, Song Y, Li H, Patel DP, Spivak AM, Alukal JP, Zhang X, Xiong C, Li PS, Hotaling JM. No evidence of severe acute respiratory syndrome-coronavirus 2 in semen of males recovering from coronavirus disease 2019. Fertil Steril. 2020 Jun;113(6):1135-1139. doi: 10.1016/j.fertnstert.2020.04.024. Epub 2020 Apr 17.</citation>
    <PMID>32482249</PMID>
  </reference>
  <reference>
    <citation>Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, Tan W. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA. 2020 May 12;323(18):1843-1844. doi: 10.1001/jama.2020.3786.</citation>
    <PMID>32159775</PMID>
  </reference>
  <reference>
    <citation>W√∂lfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, M√ºller MA, Niemeyer D, Jones TC, Vollmar P, Rothe C, Hoelscher M, Bleicker T, Br√ºnink S, Schneider J, Ehmann R, Zwirglmaier K, Drosten C, Wendtner C. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020 May;581(7809):465-469. doi: 10.1038/s41586-020-2196-x. Epub 2020 Apr 1.</citation>
    <PMID>32235945</PMID>
  </reference>
  <reference>
    <citation>Wu J, Liu J, Li S, Peng Z, Xiao Z, Wang X, Yan R, Luo J. Detection and analysis of nucleic acid in various biological samples of COVID-19 patients. Travel Med Infect Dis. 2020 Apr 18:101673. doi: 10.1016/j.tmaid.2020.101673. [Epub ahead of print]</citation>
    <PMID>32311437</PMID>
  </reference>
  <reference>
    <citation>Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Apr 7;323(13):1239-1242. doi: 10.1001/jama.2020.2648.</citation>
    <PMID>32091533</PMID>
  </reference>
  <reference>
    <citation>Yu F, Yan L, Wang N, Yang S, Wang L, Tang Y, Gao G, Wang S, Ma C, Xie R, Wang F, Tan C, Zhu L, Guo Y, Zhang F. Quantitative Detection and Viral Load Analysis of SARS-CoV-2 in Infected Patients. Clin Infect Dis. 2020 Jul 28;71(15):793-798. doi: 10.1093/cid/ciaa345.</citation>
    <PMID>32221523</PMID>
  </reference>
  <results_reference>
    <citation>Castro R, Luz PM, Wakimoto MD, Veloso VG, Grinsztejn B, Perazzo H. COVID-19: a meta-analysis of diagnostic test accuracy of commercial assays registered in Brazil. Braz J Infect Dis. 2020 Mar - Apr;24(2):180-187. doi: 10.1016/j.bjid.2020.04.003. Epub 2020 Apr 18.</citation>
    <PMID>32330437</PMID>
  </results_reference>
  <results_reference>
    <citation>Chen Y, Chen L, Deng Q, Zhang G, Wu K, Ni L, Yang Y, Liu B, Wang W, Wei C, Yang J, Ye G, Cheng Z. The presence of SARS-CoV-2 RNA in the feces of COVID-19 patients. J Med Virol. 2020 Jul;92(7):833-840. doi: 10.1002/jmv.25825. Epub 2020 Apr 25.</citation>
    <PMID>32243607</PMID>
  </results_reference>
  <results_reference>
    <citation>Infantino M, Grossi V, Lari B, Bambi R, Perri A, Manneschi M, Terenzi G, Liotti I, Ciotta G, Taddei C, Benucci M, Casprini P, Veneziani F, Fabbri S, Pompetti A, Manfredi M. Diagnostic accuracy of an automated chemiluminescent immunoassay for anti-SARS-CoV-2 IgM and IgG antibodies: an Italian experience. J Med Virol. 2020 Apr 24. doi: 10.1002/jmv.25932. [Epub ahead of print]</citation>
    <PMID>32330291</PMID>
  </results_reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>June 18, 2020</study_first_submitted>
  <study_first_submitted_qc>July 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2020</study_first_posted>
  <last_update_submitted>August 11, 2020</last_update_submitted>
  <last_update_submitted_qc>August 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara</investigator_affiliation>
    <investigator_full_name>Ricardo Reges Maia de Oliveira</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Covid</keyword>
  <keyword>Body Fluids</keyword>
  <keyword>Viral Cultures</keyword>
  <keyword>Detection Tests</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

